Sitravatinib malate is under clinical development by Mirati Therapeutics and currently in Phase II for Metastatic Uveal Melanoma. According to GlobalData, Phase II drugs for Metastatic Uveal Melanoma have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Sitravatinib malate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Sitravatinib malate overview

Sitravatinib malate is under development for the treatment of renal cell carcinoma, gallbladder cancer, advanced biliary tract cancer, oral cavity cancer, gastroesophageal junction carcinoma, non-small cell lung cancer, metastatic hepatocellular carcinoma, renal cell carcinoma, epithelial ovarian carcinoma, liposarcoma, well-differentiated or de-differentiated liposarcoma, soft tissue sarcomas, peripheral nerve sheath Tumor (neurofibrosarcoma), synovial sarcoma, rhabdomyosarcoma,  metastatic uveal melanoma and metastatic melanoma. The drug candidate is administered orally. It is a second generation multi-targeted kinase inhibitor. It inhibits RET, TRK, DDR and EphRs as well as Met, Axl and VEGFRs (VEGFR 1, 2 3), c-Met, PDGFR and KIT. It was under development for squamous cell carcinoma of head and neck, metastatic castrate-resistant prostate cancer with bone metastasis, thymoma and squamous non-small cell lung cancer, endometrial cancer and metastatic urothelial tract cancer (bladder cancer).

The drug candidate was under development for the treatment of esophageal squamous cell carcinoma and metastatic triple negative breast cancer.

Mirati Therapeutics overview

Mirati Therapeutics, a subsidiary of Bristol-Myers Squibb Co, is a clinical-stage oncology company. It carries out the research and development of novel therapeutics to address the genetic and immunological promoters of cancer. The company product pipeline includes Adagrasib (MRTX849), an oral small molecule inhibitor of KRASG12C and MRTX1133, a potent small molecule inhibitor of the KRASG12D for the treatment of colorectal and pancreatic cancer. Mirati Therapeutics also offers MRTX1133 – pancreatic cancer and Sitravatinib – Tumor, MRTX1719 -methylthioadenosine phosphorylase (MTAP) deleted cancers and MRTX0902-solid Tumors. The company partnered with Zai Lab, Beigene, Sanofi, Boehringer, Novartis and Bristol Myers Squibb, among others. It operates in Canada, the Netherlands and the US. Mirati Therapeutics is headquartered in San Diego, California, the US.

For a complete picture of Sitravatinib malate’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.